The HF-AF ENERGY Trial: Nicotinamide Riboside for the Treatment of Atrial Fibrillation in Heart Failure Patients
ConclusionThe HF-AF ENERGY trial investigates the cardioprotective effects of NR on AF burden and whether NR normalizes blood-based mitochondrial function markers and energy metabolites of the NAD metabolome in ischemic heart disease patients diagnosed with AF. The study outcomes elucidate whether NAD+ metabolism can be used as a future therapy for HF patients with AF.
Source: Cardiovascular Drugs and Therapy - Category: Cardiology Source Type: research
More News: Atrial Fibrillation | Cardiology | Cardiovascular | Heart | Heart Disease | Heart Failure | Ischemic Stroke | Laboratory Medicine | Mitochondrial Disease | Stroke | Study | Vitamin B3